Ormanns S
Pathologisches Institut, Medizinische Fakultät, Ludwig-Maximilians-Universität München, Thalkirchner Straße 36, 80337, München, Deutschland.
Pathologe. 2018 Dec;39(Suppl 2):221-224. doi: 10.1007/s00292-018-0539-2.
Ductal adenocarcinoma of the pancreas has a very poor prognosis and a rising incidence. Even after curative intent resection, which is possible in a minority of patients, most patients relapse, whereas the majority is diagnosed with inoperable or metastatic disease. That's why palliative systemic chemotherapy is the current therapeutic mainstay. Biomarker-based tumor characterization could identify potential therapy targets and enable a personalized cancer medicine. Although potentially targetable alterations occur at very low frequencies, the possible impact on patient outcome can be significant. This article summarizes some of the contributions to these aspects and gives an outlook on their clinical meaning.
胰腺导管腺癌预后很差且发病率不断上升。即便进行了有治愈意图的手术（少数患者可行），多数患者仍会复发，而大多数患者被诊断为无法手术或已转移的疾病。这就是为什么姑息性全身化疗是当前的主要治疗手段。基于生物标志物的肿瘤特征分析可以识别潜在的治疗靶点并实现个性化癌症治疗。尽管潜在的可靶向改变发生频率很低，但对患者预后的可能影响却很大。本文总结了在这些方面的一些贡献，并展望了它们的临床意义。
